Dentsply Sirona (XRAY)
Health Care · dental products and equipment · NASDAQ
Dentsply Sirona provides a comprehensive range of professional dental products, digital equipment, and clinical solutions to dental practices and laboratories worldwide.
What Dentsply Sirona does
Dentsply Sirona is a global manufacturer and distributor of professional dental products and technologies. The company provides a comprehensive portfolio including dental implants, restorative materials, endodontic instruments, orthodontic aligners, and digital imaging equipment. Its solutions are designed to support dental professionals in providing patient care across diagnostic, preventive, restorative, and surgical procedures.
Themes: dental technology, orthodontics, dental restoration, digital dentistry
Fundamentals
- Price$10.92 as of 2026-08-21 close
- Market cap$2.2B as of 2026-08-21
- 1-year return-21.4% 2025-08-21 close $13.90 → 2026-08-21 close $10.92
- P/En/a negative earnings
- Net margin-15.0% as of 2026-08-24
- Gross margin+49.5% as of 2026-08-24
- ROE-39.8% as of 2026-08-24
- Debt / equity1.65 as of 2026-08-24
- Revenue growth (YoY)-0.8% as of 2026-08-24
- Revenue CAGR (3y)-2.1% SEC XBRL
- Beta0.85 as of 2026-08-24
- Last reported earnings2026-05-05 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +5.5%; at least 5 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How XRAY compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- indicated dividend yieldtop 10% 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
XRAY is not currently in any published Top 10 list. Its scores are below.
Long-term score
27.3 #961 of 987 scored · #55 of 57 in Health Care
Valuation 75th (price to book 1.6) and capital return 71st (consecutive years of dividend increases 5 years); weakest is profitability (1st, return on equity -39.8%, operating margin -8.5%).
Short-term score
28.5 #1659 of 1,704 scored · #233 of 240 in Health Care
Catalysts 49th: open-market insider buys in 90 days 24, the analyst consensus rating is unchanged since the prior reading; momentum 44th: near the bottom of its 14-day range (oversold); weakest is setup 13th: day-to-day price swings are unusually wide versus its own recent history (wider than about 98% of the past ~6 months).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage (FY2025)
Exceeded at least one reported measure. In FY2025, XRAY's dividend exceeded at least one reported measure of what it earned or generated (free-cash-flow payout 123%). A payout above 100% in one year is not necessarily unsustainable, but it is not fully covered by that measure.
- Earnings payoutnot assessable earnings were not positive that year
- Free-cash-flow payout123% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Dentsply Sirona looks technically
Dentsply Sirona (XRAY) is trading 7.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 7 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 2 trading days ago. It is 26.5% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 7.3% below its 200-day average, the long-term trend line — a long-term downtrend | -7.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $11.99 | $11.99 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $11.78 | $11.78 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 23 calendar days ago — the swings before that are what the structure reading is measured on | 23 sessions |
| Wave structure | its recent swings can be read as a completed five-part upward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes above 14.435. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave upward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 7 trading days ago — a "golden cross", a bullish long-term signal | 7 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with sellers in control | 26.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30) | 36.2 |
|---|---|---|
| Position in its 14-day range | it is trading right at the bottom of its 14-day range ($10.75 to $14.35) — its "stochastic" reading is 5 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 4.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $14.86 | $14.86 |
|---|---|---|
| From the 52-week high | it is 26.5% below its 52-week high (its highest price of the past year) | -26.5% |
| Above the 52-week low | it is 16.0% above its 52-week low (its lowest price of the past year) | +16.1% |
| Below the 52-week high | it is 26.5% below its highest point of the past year | 26.5% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day high about 14 trading days ago | 14 sessions |
| All-time high | its highest closing price on record is $69.54 (set on 2021-05-10) | $69.54 |
| Given back of the 52-week move | over the past year its closes ranged ($9.64 to $14.68), and it has recovered roughly a quarter of its fall from last year’s high — 25% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $12.75 to $12.92. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 25.4% |
| From the all-time high | it is 84.3% below its all-time high | -84.3% |
| Nearest price level | it is trading 7.7% below a resistance level at $11.76 — a price it turned at three times since 2025-10-10, most recently on 2026-02-03. Since 2024-08-21 it has 1 such level below the current price and 16 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +7.7% |
| All-time low | its lowest closing price on record is $9.41 (set on 2026-05-19) | $9.41 |
| Above the all-time low | it is 16.0% above its all-time low | +16.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 98% of the past ~6 months) | 98th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.5569 between its high and its low — about 5.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.5569 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $9.96 and $14.85 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $9.96 – $12.41 – $14.85 |
| Typical daily range (% of price) | its price moves about 5.1% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.1% |
| Stretch from the 200-day average | it is trading 1.5 daily ranges below its 200-day average price (7.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.5 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.67× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.9% since the prior reading | -0.9% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 8 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 8 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.7% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.7% |
|---|---|---|
| Gap filled | a 3.1% gap up opened on 2026-08-07 has been "filled" 10 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 10 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 22.3 percentage points (the stock lost 20.0% while the market gained 2.3%) | -22.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 6.9 percentage points (the stock gained 10.0% while the market gained 3.1%) | +6.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 24.0 percentage points (the stock lost 12.9% while the market gained 11.1%) | -24.0% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 41.9 percentage points (the stock lost 21.4% while the market gained 20.5%) | -41.9% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 6.8% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 4.7% of the share price. | -6.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 8% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $11.89 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | -8.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $11.62 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | -6.0% |
Price levels it has turned at before
XRAY last closed at $10.92 on 2026-08-21. Since 2024-08-21 it has turned at 1 price below its last close and 16 above; the nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $11.76 | Resistance | 7.7% above the last close | turned there three times · 2025-10-10 to 2026-02-03 |
| $12.16 | Resistance | 11.3% above the last close | turned there four times · 2025-04-11 to 2026-03-26 |
| $9.44 | Support | 13.6% below the last close | turned there twice · 2026-05-19 to 2026-06-04 |
| $12.43 | Resistance | 13.8% above the last close | turned there three times · 2025-08-11 to 2026-07-23 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $14.44.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market · At the bottom of its 14-day range (stochastic below 20) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.89 mean, 1=Strong Buy…5=Strong Sell) — 16 analysts
- Mean price target$13.59 range $9.00 – $17.00; median $14.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for XRAY
- Consensus EPS estimate$0.3175 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant goodwill and intangible asset impairment risks","Exposure to global economic conditions and foreign currency fluctuations","Intense competition within the dental products and technology markets"]
What changed in the latest 10-Q
AI-assisted comparison of XRAY's 10-Q filed 2026-05-05 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to 'court challenges' regarding tariffs in the newer filing (2026-05-05)
- Added disclosure that tariffs 'remain subject to evolving modifications and court challenges' (2026-05-05)
- Added statement: 'We continue to monitor and evaluate the ongoing and potential impacts on our supply chain, costs, net sales, and profitability of the tariffs, changes in trade policy, whether implemented or proposed, and court rulings on the legality of certain tariffs.' (2026-05-05)
- Removed:
- Removed sentence about company experiencing higher prices for certain raw materials, including electronic components, and negative impact on margins from the macroeconomic conditions section (2025-11-06 version removed from 2026-05-05)
- Removed sentence: 'The Company may not be successful in its efforts to fully mitigate or offset the impacts of cost inflation.' (2025-11-06 version removed from 2026-05-05)
- Removed specific tariff rate details: 'including a baseline 10% tariff on all foreign goods, a 15% tariff in lieu of the baseline tariff on goods from countries in the European Union, and higher incremental tariff rates on goods imported from other specified nations' (2025-11-06 version removed from 2026-05-05)
- Removed reference to 'May 2024' related to Ukraine response (2025-11-06 version removed from 2026-05-05)
- Reworded:
- History changed from '138-year history' (2025-11-06) to '139-year history' (2026-05-05)
- Cloud solution reference changed from 'cloud-enabled solutions' (2025-11-06) to 'cloud-enabled software solutions' (2026-05-05)
- Orthodontic and Implant Solutions segment description: removed 'and dental professional-directed aligner solutions' and replaced with 'and digital orthodontic solutions' (2026-05-05)
- Wellspect Healthcare description simplified from 'Wellspect is one of the world's leading manufacturers of intermittent urinary catheters, with LoFric as its most known brand. To help those with chronic or severe constipation, Wellspect also offers an advanced irrigation system, Navina, which combines...' (2025-11-06) to 'Wellspect Healthcare is a leading global manufacturer and provider of innovative medical devices, including catheters to help people suffering from urinary retention and advanced irrigation systems to help people suffering from chronic or severe constipation, which combine...' (2026-05-05)
- Macroeconomic timeframe changed from 'throughout the remainder of 2025' (2025-11-06) to 'for the remainder of 2026' (2026-05-05)
- Form 10-K reference changed from '2024 Form 10-K for the fiscal year ended December 31, 2024' (2025-11-06) to '2025 Form 10-K for the fiscal year ended December 31, 2025' (2026-05-05)
- Tariff policy description changed from 'implemented or is in the process of implementing' (2025-11-06) to 'implemented and could further implement' (2026-05-05)
- Israel data updated: period changed from 'nine months ended September 30, 2025' (2025-11-06) to 'three months ended March 31, 2026' (2026-05-05); net sales percentage remained approximately 3% but OIS segment percentage changed from 'approximately 13%' (2025-11-06) to 'approximately 14%' (2026-05-05); net assets changed from '$166 million as of September 30, 2025' (2025-11-06) to '$131 million as of March 31, 2026' (2026-05-05)
- Inventory listed before cash in Israel net assets description (2026-05-05) versus cash listed before inventory (2025-11-06)
- Notes:
- Both documents appear truncated at the end; the older filing text cuts off mid-sentence at 'in response to ongoing mili' and the newer filing cuts off at 'not materia', so a complete comparison of the geopolitical conflicts section cannot be made
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
6 open-market purchases and 0 open-market sales by insiders in the last 90 days.
- Last 90 days6 buys ($617199) · 0 sells — 6 buying insiders
- Last 180 days6 buys ($617199) · 0 sells — 6 buying insiders
Cluster buying: 6 different insiders reported open-market purchases (SEC code P) of XRAY within a 30-day window between 2026-06-11 and 2026-06-15. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-15. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about XRAY's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 2 matched disclosures for XRAY from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding XRAY as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 30,559,215
- Reported value $354,486,894
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 3 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
XRAY had 23,604,124 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
XRAY had 11.8% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.75 days to cover at the same settlement.
- Reported short interest (shares) 23,604,124
- Short interest (% of shares outstanding) 11.8%
- Prior settlement (shares) 29,935,825
- Reported change -21.15%
- Days to cover (reported) 4.75
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Envista Holdings (NVST)
- Straumann Group (STMN.SW)
- Align Technology (ALGN)
- Henry Schein (HSIC)
- Patterson Companies (PDCO)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare XRAY vs…
Frequently asked questions
What does Dentsply Sirona (XRAY) do?
Dentsply Sirona is a global manufacturer and distributor of professional dental products and technologies. The company provides a comprehensive portfolio including dental implants, restorative materials, endodontic instruments, orthodontic aligners, and digital imaging equipment. Its solutions are designed to support dental professionals in providing patient care across diagnostic, preventive, restorative, and surgical procedures.
What sector is Dentsply Sirona (XRAY) in?
Dentsply Sirona (XRAY) is classified in the Health Care sector. Its industry is dental products and equipment. It trades on NASDAQ.
Does XRAY pay a dividend?
Yes — Dentsply Sirona (XRAY) pays a dividend, with an indicated yield of about 5.50% and at least 5 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-08-24). Informational only — not financial advice.
Who are Dentsply Sirona's (XRAY) competitors?
Notable peers of Dentsply Sirona (XRAY) include Envista Holdings, Straumann Group, Align Technology, Henry Schein and Patterson Companies. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in XRAY?
Yes — we hold 2 matched STOCK Act disclosures for XRAY from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Dentsply Sirona (XRAY) overbought or oversold right now?
Dentsply Sirona (XRAY) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 36, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on XRAY come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.